Apremilast and Adalimumab in Psoriatic Arthritis Patients

Sponsor
Tanta University
Study ID
NCT07398651
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Adalimumab — DRUG
    PsA patients who will receive Adalimumab with methotrexate therapy for 3 months
  • Apremilast — DRUG
    PsA patients who will receive Apremilast with methotrexate therapy for 3 months

Study Details

The aim of this work is to compare the efficacy of Apremilast combined with Methotrexate versus Adalimumab combined with Methotrexate

Key Dates

Start date
Dec 30, 2026
Status verified
Jan 2026
Primary completion
Dec 30, 2026
Completion
Dec 30, 2026

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Group I
    consists of 30 PsA patients who will receive Adalimumab with methotrexate therapy for 3 months.
  • Experimental: Group II
    consists of 30 PsA patients who will receive Apremilast with methotrexate therapy for 3 months.

Primary Outcome Measure

Disease Activity Index for Psoriatic Arthritis [ Time Frame: 3 months ]

Central Contacts

Related Studies